Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Aggressive B-cell lymphomas.

Naresh KN, Magrath I, Raphael M, Leoncini L.

Adv Hematol. 2012;2012:604603. doi: 10.1155/2012/604603. Epub 2012 Mar 14. No abstract available.

2.

B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.

Li S, Lin P, Fayad LE, Lennon PA, Miranda RN, Yin CC, Lin E, Medeiros LJ.

Mod Pathol. 2012 Jan;25(1):145-56. doi: 10.1038/modpathol.2011.147. Epub 2011 Oct 14.

3.

Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively.

Tracey L, Pérez-Rosado A, Artiga MJ, Camacho FI, Rodríguez A, Martínez N, Ruiz-Ballesteros E, Mollejo M, Martinez B, Cuadros M, Garcia JF, Lawler M, Piris MA.

J Pathol. 2005 Jun;206(2):123-34.

PMID:
15880597
4.

Prognostic factors in indolent and aggressive lymphomas and its influence on disease outcome.

Zodelava M, Betaneli M, Tsartsidze E, Kharabadze M.

Georgian Med News. 2009 Feb;(167):32-6.

PMID:
19276466
5.

Altered subcellular localization of c-Myc protein identifies aggressive B-cell lymphomas harboring a c-MYC translocation.

Ruzinova MB, Caron T, Rodig SJ.

Am J Surg Pathol. 2010 Jun;34(6):882-91. doi: 10.1097/PAS.0b013e3181db83af.

PMID:
20442643
6.

Non-Hodgkin's lymphomas in Greece according to the WHO classification of lymphoid neoplasms. A retrospective analysis of 810 cases.

Economopoulos T, Papageorgiou S, Dimopoulos MA, Pavlidis N, Tsatalas C, Symeonidis A, Foudoulakis A, Pectasides D, Rontogianni D, Rizos E, Chalkia P, Anagnostopoulos A, Melachrinou M, Papageorgiou E, Fountzilas G.

Acta Haematol. 2005;113(2):97-103.

PMID:
15802887
7.

A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling.

Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF, Bernd HW, Cogliatti SB, Dierlamm J, Feller AC, Hansmann ML, Haralambieva E, Harder L, Hasenclever D, Kühn M, Lenze D, Lichter P, Martin-Subero JI, Möller P, Müller-Hermelink HK, Ott G, Parwaresch RM, Pott C, Rosenwald A, Rosolowski M, Schwaenen C, Stürzenhofecker B, Szczepanowski M, Trautmann H, Wacker HH, Spang R, Loeffler M, Trümper L, Stein H, Siebert R; Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe.

N Engl J Med. 2006 Jun 8;354(23):2419-30.

8.

Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression. p27/KIP1-cyclin D3 colocalization in tumor cells.

Sánchez-Beato M, Camacho FI, Martínez-Montero JC, Sáez AI, Villuendas R, Sánchez-Verde L, García JF, Piris MA.

Blood. 1999 Jul 15;94(2):765-72.

9.

Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.

Hagemeister FB.

Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. Epub 2002 Apr 12. Review.

PMID:
12042984
10.

MYC and aggressive B-cell lymphomas.

Slack GW, Gascoyne RD.

Adv Anat Pathol. 2011 May;18(3):219-28. doi: 10.1097/PAP.0b013e3182169948. Review.

PMID:
21490439
11.

Primary natural killer/T-cell lymphomas of the oral cavity are aggressive neoplasms.

Yin HF, Jamlikhanova V, Okada N, Takagi M.

Virchows Arch. 1999 Oct;435(4):400-6.

PMID:
10526003
12.

[Epitheliotropic lymphomas: better identification for improved treatment].

Bagot M.

Bull Acad Natl Med. 2010 Oct;194(7):1365-72. Review. French.

PMID:
22043631
13.

Double-hit B-cell lymphomas.

Aukema SM, Siebert R, Schuuring E, van Imhoff GW, Kluin-Nelemans HC, Boerma EJ, Kluin PM.

Blood. 2011 Feb 24;117(8):2319-31. doi: 10.1182/blood-2010-09-297879. Epub 2010 Nov 30. Review.

14.

Transcriptional profiling suggests that secondary and primary large B-cell lymphomas of the gastrointestinal (GI) tract are blastic variants of GI marginal zone lymphoma.

Barth TF, Barth CA, Kestler HA, Michl P, Weniger MA, Buchholz M, Möller P, Gress T.

J Pathol. 2007 Feb;211(3):305-13.

PMID:
17152084
15.

The molecular background of aggressive B cell lymphomas as a basis for targeted therapy.

de Jong D, Balagué Ponz O.

J Pathol. 2011 Jan;223(2):274-82. doi: 10.1002/path.2807. Epub 2010 Nov 16. Review.

PMID:
21125680
16.

Adult B-cell lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior.

McClure RF, Remstein ED, Macon WR, Dewald GW, Habermann TM, Hoering A, Kurtin PJ.

Am J Surg Pathol. 2005 Dec;29(12):1652-60.

PMID:
16327438
17.

Gastrointestinal lymphomas of T- and B-cell types.

Isaacson PG.

Mod Pathol. 1999 Feb;12(2):151-8. Review.

PMID:
10071340
18.

[Large B-cell lymphomas: variants and entities].

Anagnostopoulos I, Stein H.

Pathologe. 2000 Mar;21(2):178-89. Review. German.

PMID:
10840822
19.

Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease.

Nguyen PL, Harris NL, Ritz J, Robertson MJ.

Am J Pathol. 1996 Mar;148(3):847-53. Erratum in: Am J Pathol 1996 Jul;149(1):346.

20.

[R.E.A.L. classification of non-Hodgkin lymphoma from the clinico-oncologic viewpoint].

Meusers P, Brittinger G.

Praxis (Bern 1994). 1998 Jun 3;87(23):793-800. German.

PMID:
9654985

Supplemental Content

Support Center